Treats thrombocytopenia. Sold as Tavalisse. Every FDA application for this active ingredient: 1 branded and 1 generic.
As of Nov 15, 2026, FDA lists 2 applications for Fostamatinib Disodium (sold as Tavalisse), first approved Apr 17, 2018, with 0 new uses approved and 0 published complete response letters.
| Product | Part | Spending, 2025 | Change | Beneficiaries |
|---|---|---|---|---|
| Tavalisse | Part D | $92.6M | +95% | 948 |
| Fostamatinib for Treating Acute Respiratory Distress Syndrome (ARDS) in Hospitalized AdultsAcute Respiratory Distress Syndrome, ARDS · Inova Health Care Services | Phase 2 | Not yet recruiting | Aug 21, 2024 |
| A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic AnemiaWarm Antibody Autoimmune Hemolytic Anemia · Rigel Pharmaceuticals | Phase 3 | Enrolling by invitation | Oct 25, 2019 |
| Apr 17, 2018 | TavalisseNDA 209299 · New molecular entity | Rigel Pharms | 1 | Marketed |
| Jun 17, 2026 | Fostamatinib DisodiumANDA 217329 | Annora Pharma | 0 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
